All In Biotech

Drug Trial Radar · NCT07546149

A Multiple Ascending Dose Study of LW402 in Healthy Volunteers

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LW402 Tablets Following Multiple Doses in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

36

Actual

Start

Oct 15, 2025

Primary completion

Dec 9, 2025

Study completion Dec 31, 2025

Sponsor

Sponsor type
Industry
First posted
Apr 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 1, double-blind (sponsor open), placebo controlled study will assess the safety, tolerability and pharmacokinetics of multiple doses of LW402 tablets in healthy volunteers.

Conditions

  • Safety Evaluation of Escalating Doses

Interventions

  • ExperimentalDrug

    LW402 Tablets

  • PlaceboDrug

    LW402 Placebo Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability AssessmentTime frame: up to 9 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Shandong First Medical University

    Jinan, Shangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.